Hour9 Launches AI Automation Agency with Process-First Approach, Challenging Assumption That Businesses Should Maximize AI Integration 
Sixty-Six Capital Expands Effective Bitcoin Exposure with Option for up to 200 BTC and Move to Direct Holdings 
NTG Clarity to Announce Second Quarter Financial Results on August 27, 2026 with Earnings Call to Follow 
SonicStrategy Reports Q2 2026 Staking Revenue and Reduced Monthly Burn 
QSE Closes Second Tranche of Private Placement of $6 Million Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Bluejay Therapeutics, Inc. a private clinical…
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to…
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to…
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
– Phase 2a NASH protocol on track to be submitted to the IND in Q4…
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
– Phase 2a NASH protocol on track to be submitted to the IND in Q4…
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support…
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support…
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2…
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2…
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or…
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or…
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700…
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company –…
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700…
Tilray Brands, Inc. to Announce First Quarter 2024 Financial Results on October 4, 2023
NEW YORK and LEAMINGTON, Ontario, Sept. 21, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company –…
Tilray Brands, Inc. to Announce First Quarter 2024 Financial Results on October 4, 2023
NEW YORK and LEAMINGTON, Ontario, Sept. 21, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
— Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”),…